NovoCure Ltd (NASDAQ:NVCR) does about 1.53M shares in volume on a normal day but saw 989559 shares change hands in the recent trading day. The company now has a market cap of 2.11B USD. Its current market price is $19.46, marking a decrease of -4.98% compared to the previous close of $20.48. The 52 week high reached by this stock is $31.81 whilst the lowest price level in 52 weeks is $10.87. The script in recent trading has seen the stock touch a high of $200 and a low of $14.5.
NovoCure Ltd (NVCR) has a 20-day trading average at $19.44 and the current price is -38.82% off the 52-week high compared with 79.02% distance from its 52-week low. The 50-day simple moving average of the closing price is $19.77 and its 200-day simple moving average is $15.73. If we look at the stock’s price movements over the week, volatility stands at 7.17%, which decreases to 6.96% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 49.16 to suggest the stock is neutral.
The consensus objective for the share price is $26.17, suggesting that the stock has a potential upside of 25.64% over the period. The median price target is 44.4% away from the current levels at $35.
1 analysts have rated it as a buy and 3 have advised that investors hold their positions. The consensus recommendation rating is Hold and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on November 20, 2023 when JP Morgan resumed the stock to “Neutral” and issued a price target of $15. H.C. Wainwright downgraded the stock to “Neutral” from Buy on August 28, 2023 at a price target of $85-$25. Piper Sandler upgraded its price target at $45.
NovoCure Ltd (NVCR) stock is down -16.64% over the week and 21.62% over the past month. Its price is 30.34% year-to-date and -31.84% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at -0.33 and -1.37 for whole year. Expected sales for next quarter are $147.69M, which analysts say will come at $580.44M for the current fiscal year and next year at $612.58M. In addition, estimates put the company’s current quarterly revenue at an average of $143.85M.
Its 12-month price target is $35. To reach the target analysts have set, the stock logically needs to grow 25.64 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $14.5, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $200.
The company has a return on investment of -16.27% and return on equity of -43.40%. The beta has a value of 0.74. Price to book ratio is 5.81 and price to sales ratio is 3.83.
